The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.

MLA

Joubert, Michael, et al. “The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.” Diabetes, vol. 66, no. 4, Apr. 2017, pp. 1030–40. EBSCOhost, https://doi.org/10.2337/db16-0733.

APA

Joubert, M., Jagu, B., Montaigne, D., Marechal, X., Tesse, A., Ayer, A., Dollet, L., Le May, C., Toumaniantz, G., Manrique, A., Charpentier, F., Staels, B., Magré, J., Cariou, B., Prieur, X., & Cariou, B. (2017). The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model. Diabetes, 66(4), 1030–1040. https://doi.org/10.2337/db16-0733

Chicago

Joubert, Michael, Benoît Jagu, David Montaigne, Xavier Marechal, Angela Tesse, Audrey Ayer, Lucile Dollet, et al. 2017. “The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.” Diabetes 66 (4): 1030–40. doi:10.2337/db16-0733.